Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:CAMP

CAMP4 Therapeutics (CAMP) Stock Price, News & Analysis

CAMP4 Therapeutics logo

About CAMP4 Therapeutics Stock (NASDAQ:CAMP)

Advanced Chart

Key Stats

Today's Range
$3.52
$4.67
50-Day Range
$0.40
$4.00
52-Week Range
$1.31
$12.30
Volume
58,479 shs
Average Volume
162,873 shs
Market Capitalization
$32.05 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$16.50
Consensus Rating
Buy

Company Overview

CalAmp Corp. is a global technology solutions provider founded in 1981 that offers businesses and consumers a wide range of software and hardware products and services worldwide. The company is headquartered in Irvine, California, with additional offices in Europe and Asia. CalAmp has a history of innovation and has received numerous industry awards for its products and services. Key highlights of the company's achievements include acquiring LoJack Corporation, a leader in vehicle theft recovery and advanced fleet management solutions and the launch of CalAmp iOn, a cloud-based platform for managing IoT (Internet of Things) devices.

Calamp's revenue has declined an average of -7.95% yearly, 12.07 percentage points lower than the US Communication Equipment industry's average revenue growth rate of 4.13%. CalAmp shed its satellite communications business in 2020, which resulted in a one-time gain of $85 million. CalAmp's stock performance has declined since 2018 from a peak of around $24.00 a share to a low of approximately $3.00. Despite this, the company could gain momentum as it recently announced a restructuring plan to transition to a cloud-based IOT platform.  

CalAmp operates in the technology solutions industry, rapidly evolving due to the increasing use of digital technologies across various sectors. The company's main competitors include industry giants like Cisco Systems, Inc. and Honeywell International Inc., as well as smaller companies like Fleet Complete and Orbcomm Inc. The industry is subject to various regulatory and political issues, including data privacy and security concerns, which can significantly impact the industry's growth and profitability.

CalAmp's management team is led by CEO Jeff Gardner, who has over 25 years of experience in the technology industry. Other key team members include the recent addition of CFO Kurt Binder, who has a history of succeeding in challenging business environments and CTO Anand Rau, who has 25 years of strategic management experience in delivering enterprise-class, mission-critical applications. 

CalAmp has identified several potential growth opportunities, including expanding its IoT platform, CalAmp iOn, into new markets, such as healthcare and agriculture. The company is also exploring new product launches, such as its recently launched connected car solution, which allows vehicle owners to monitor and manage their vehicles remotely. Additionally, CalAmp is actively pursuing acquisitions to expand its product and service offerings and increase its market share.

The technology industry is highly competitive, and CalAmp faces significant competition from larger, more established companies. The industry is also subject to rapid technological change, which can quickly make existing products and services obsolete. CalAmp must continue to innovate and stay ahead of the curve to maintain its market position. Additionally, the industry is subject to regulatory and political risks, including data privacy and security concerns, which can impact the industry's growth and profitability.

CAMP4 Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
49th Percentile Overall Score

CAMP MarketRank™: 

CAMP4 Therapeutics scored higher than 49% of companies evaluated by MarketBeat, and ranked 524th out of 921 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    CAMP4 Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.17, and is based on 5 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    CAMP4 Therapeutics has only been the subject of 1 research reports in the past 90 days.

  • Read more about CAMP4 Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for CAMP4 Therapeutics are expected to grow in the coming year, from ($4.99) to ($2.89) per share.

  • Price to Book Value per Share Ratio

    CAMP4 Therapeutics has a P/B Ratio of 0.51. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Short Interest

    There is no current short interest data available for CAMP.
  • Dividend Yield

    CAMP4 Therapeutics does not currently pay a dividend.

  • Dividend Growth

    CAMP4 Therapeutics does not have a long track record of dividend growth.

  • Short Interest

    There is no current short interest data available for CAMP.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for CAMP4 Therapeutics this week, compared to 0 articles on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, CAMP4 Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    33.60% of the stock of CAMP4 Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Read more about CAMP4 Therapeutics' insider trading history.
Receive CAMP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for CAMP4 Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

CAMP Stock News Headlines

A grave, grave error.
Famed financial analyst, Porter Stansberry, calls this technology “The Final Frontier” because it holds the key to unlocking technological breakthroughs we once thought were impossible. And it may just be the only thing capable of bringing America back from the brink of recession – despite Washington’s incompetence and addiction to reckless spending. That’s why Elon Musk, Jeff Bezos, Jensen Huang, and even Bill Gates are pouring billions into the infrastructure behind it.
See More Headlines

CAMP Stock Analysis - Frequently Asked Questions

CAMP4 Therapeutics Corporation (NASDAQ:CAMP) announced its quarterly earnings data on Tuesday, May, 13th. The Wireless communications provider reported ($0.62) EPS for the quarter, beating analysts' consensus estimates of ($0.70) by $0.08. The Wireless communications provider had revenue of $0.86 million for the quarter, compared to analysts' expectations of $0.10 million.

Shares of CAMP4 Therapeutics reverse split on the morning of Friday, February 2nd 2024.The 1-23 reverse split was announced on Friday, February 2nd 2024. The number of shares owned by shareholders was adjusted after the closing bell on Friday, February 2nd 2024. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

CAMP4 Therapeutics subsidiaries include these companies: LoJack, Gulfstream Telematics, SmartLink Radio Networks, CalAmp Wireless Networks Inc., Skybility, Boisen S.A., CalAmp Importation and Leasing of Tracking Equipment Ltd., and others.

CAMP4 Therapeutics (CAMP) raised $75 million in an initial public offering on Friday, October 11th 2024. The company issued 6,820,000 shares at a price of $11.00 per share.

Top institutional shareholders of CAMP4 Therapeutics include Victory Capital Management Inc. (0.41%), Bank of New York Mellon Corp (0.07%), Goldman Sachs Group Inc. (0.06%) and New York State Common Retirement Fund (0.03%). Insiders that own company stock include Polaris Management Co Vii, L, B Riley Asset Management, Llc, Jeffery R Gardner and Jason Cohenour.
View institutional ownership trends
.

Based on aggregate information from My MarketBeat watchlists, some other companies that CAMP4 Therapeutics investors own include Zimmer Biomet (ZBH), Union Pacific (UNP), Charter Communications (CHTR), NVIDIA (NVDA), PayPal (PYPL), MercadoLibre (MELI) and Meta Platforms (META).

Company Calendar

Last Earnings
5/13/2025
Today
6/23/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Communications Equipment
Current Symbol
NASDAQ:CAMP
Employees
644
Year Founded
1981

Price Target and Rating

Average Stock Price Target
$16.50
High Stock Price Target
$23.00
Low Stock Price Target
$8.00
Potential Upside/Downside
+937.7%
Consensus Rating
Buy
Rating Score (0-4)
3.17
Research Coverage
6 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$650 thousand
Price / Cash Flow
N/A
Book Value
$3.13 per share
Price / Book
0.51

Miscellaneous

Free Float
13,387,000
Market Cap
$32.05 million
Optionable
No Data
Beta
N/A

Social Links

The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

This page (NASDAQ:CAMP) was last updated on 6/24/2025 by MarketBeat.com Staff
From Our Partners